
    
      Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease.
      Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of
      response failure. Novartis provided supplies of imatinib for all patients included in the
      study.
    
  